Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1
Intratumoral injection of an investigational agent, BO-112, combined with pembrolizumab (Keytruda) demonstrated promising efficacy in certain patients with advanced melanoma refractory to anti-PD-1-based therapy, according to results from a single-arm phase II trial. Ten of 40 evaluable patients responded to treatment — six partial and four complete responses — meeting the study’s primary endpoint of […]